Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida

被引:115
作者
Doolin, MT
Barbaux, S
McDonnell, M
Hoess, K
Whitehead, AS
Mitchell, LE
机构
[1] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Ctr Pharmacogenet, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[5] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA
关键词
D O I
10.1086/344209
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
There is currently considerable interest in the relationship between variation in genes that are involved in the folate-homocysteine metabolic axis and the risk of spina bifida. The evaluation of this relationship is, however, complicated by the potential involvement of both the maternal and the embryonic genotype in determination of disease risk. The present study was designed to address questions regarding both maternal and embryonic genetic risk factors for spina bifida by use of the two-step transmission/disequilibrium test. Analysis of data on variants of two genes involved in homocysteine remethylation/methionine biosynthesis-methionine synthase (MTR) A2756G and methionine synthase reductase (MTRR) A66G-provided evidence that both variants influence the risk of spina bifida via the maternal rather than the embryonic genotype. For both variants, the risk of having a child with spina bifida appears to increase with the number of high-risk alleles in the maternal genotype: MTR (R-1 = 2.16, 95% CI 0.92-5.06; R-2 = 6.58, 95% CI 0.87- 49.67) and MTRR (R-1 = 2.05, 95% CI 1.05-3.99; R-2 = 3.15, 95% CI 0.92-10.85). These findings highlight the importance of considering both the maternal and embryonic genotype when evaluating putative spina bifida susceptibility loci.
引用
收藏
页码:1222 / 1226
页数:5
相关论文
共 29 条
[1]  
Barbaux S, 2000, CLIN CHEM, V46, P907
[2]  
Christensen B, 1999, AM J MED GENET, V84, P151, DOI 10.1002/(SICI)1096-8628(19990521)84:2<151::AID-AJMG12>3.0.CO
[3]  
2-T
[4]  
CURTIS D, 1995, AM J HUM GENET, V56, P811
[5]  
EWENS WJ, 1995, AM J HUM GENET, V57, P455
[6]   The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations [J].
Gaughan, DJ ;
Kluijtmans, LAJ ;
Barbaux, S ;
McMaster, D ;
Young, IS ;
Yarnell, JWG ;
Evans, A ;
Whitehead, AS .
ATHEROSCLEROSIS, 2001, 157 (02) :451-456
[7]  
Gilliam DM, 1997, ALCOHOL CLIN EXP RES, V21, P28
[8]   Why are the genes that cause risk of human neural tube defects so hard to find? [J].
Harris, MJ .
TERATOLOGY, 2001, 63 (05) :165-166
[9]   Comorbidity of 5,10-methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms and risk for neural tube defects [J].
Johanning, GL ;
Tamura, T ;
Johnston, KE ;
Wenstrom, KD .
JOURNAL OF MEDICAL GENETICS, 2000, 37 (12) :949-951
[10]   Altered folate metabolism and disposition in mothers affected by a spina bifida pregnancy:: Influence of 677c → t methylenetetrahydrofolate reductase and 2756a → g methionine synthase genotypes [J].
Lucock, M ;
Daskalakis, I ;
Briggs, D ;
Yates, Z ;
Levene, M .
MOLECULAR GENETICS AND METABOLISM, 2000, 70 (01) :27-44